BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TMC435: Phase III amended

Medivir said that after discussions with FDA the primary endpoint for the Phase III QUEST-2 trial has been changed to SVR12 from SVR24. The double-blind, placebo-controlled, international trial is evaluating 150 mg oral TMC435 daily for 12 weeks in combination with either Pegasys...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >